Sana Biotechnology adjusts director board class balance
Sana Biotechnology, Inc. adjusted the classification of one board seat to comply with its Amended and Restated Certificate of Incorporation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Sana Biotechnology, Inc. adjusted the classification of one board seat to comply with its Amended and Restated Certificate of Incorporation. On April 22, 2026, director Steven D. Harr, M.D. resigned as a Class I director and was immediately re-appointed as a Class III director.
The filing states this change was made solely to rebalance the three director classes, and that Dr. Harr’s board service is considered continuous. Following this reclassification, the Board now has three directors in each of Class I, Class II, and Class III.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board class sizes: 3 directors per class
Board classes: Three classes (I, II, III)
Director term endpoint: 2027 annual meeting
3 metrics
Board class sizes
3 directors per class
After reclassification of Steven D. Harr, M.D.
Board classes
Three classes (I, II, III)
Classified board structure under Certificate of Incorporation
Director term endpoint
2027 annual meeting
New term for Class III director seat held by Steven D. Harr, M.D.
Key Terms
Class I director, Class III director, Amended and Restated Certificate of Incorporation, Emerging growth company, +1 more
5 terms
Class I director financial
"one of its Class I directors (with a term expiring at the Company’s 2028 annual meeting of stockholders)"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
Class III director financial
"reclassified to a Class III director (with a term expiring at the Company’s 2027 annual meeting of stockholders)"
A Class III director is a board member placed in one of the numbered groups used by companies with a staggered (or “classified”) board; that director’s seat typically comes up for election in the third year of a three-year rotation. For investors this matters because staggered terms create continuity but also make it harder to replace the whole board quickly, affecting shareholder influence, takeover dynamics and how fast new strategy or accountability can be implemented — like replacing only some players on a sports team each season instead of the whole roster at once.
Amended and Restated Certificate of Incorporation regulatory
"in accordance with the Company’s Amended and Restated Certificate of Incorporation"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Sana Biotechnology (SANA) disclose in this 8-K?
Sana Biotechnology reclassified one board seat, moving director Steven D. Harr, M.D. from Class I to Class III. This administrative step keeps his service continuous while rebalancing the three director classes to align with the company’s Certificate of Incorporation.
Why did Sana Biotechnology (SANA) reclassify Steven Harr’s board seat?
The board reclassified Steven Harr’s seat to achieve a more equal balance of directors among Class I, II, and III. The change was made to comply with Sana Biotechnology’s Amended and Restated Certificate of Incorporation governing the company’s classified board structure.
Does Steven Harr’s reclassification at Sana Biotechnology affect his board service?
The filing states that Steven Harr’s service on the board is deemed to have continued uninterrupted. He resigned as a Class I director and was immediately re-appointed as a Class III director, so there is no gap or break in his board service.
What are the new board class sizes at Sana Biotechnology (SANA)?
After the reclassification, Sana Biotechnology’s board now consists of three directors in each of Class I, Class II, and Class III. This equal distribution aligns the board composition with the structure set out in the company’s Certificate of Incorporation.
When did Sana Biotechnology’s board approve the director reclassification?
On April 22, 2026, the board accepted Steven Harr’s contingent resignation as a Class I director and immediately re-appointed him as a Class III director. The actions became effective immediately prior to his re-appointment as a Class III director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
